AACC 2017 Focus on CRISPR and Futuristic Testing Devices
|
By LabMedica International staff writers Posted on 01 Aug 2017 |
At the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services, over 750 exhibitors displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation. But the focus was largely on clustered regularly interspaced short palindromic repeats (CRISPR), Star Trek-like testing devices, and antibiotic resistance.
Kalorama Information, (New York, NY, USA), an independent medical market research firm, estimates the market for CRISPR to be worth USD 28 billion and believes that gene editing is reaching mainstream testing. According to experts, CRISPR will be first used to treat people for blood-related diseases in a way similar to a bone marrow transplant, but to correct a person’s own blood-producing cells instead of implanting donated ones.
The 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from July 30–August 3, also featured a talk by CRISPR co-inventor Jennifer Doudna, PhD, on the future of genome engineering using this revolutionary tool, as well as a plenary on the clinical lab's critical role in combating the antibiotic resistance crisis.
Among the exhibitors at the event was Final Frontier Medical Devices, which presented its real-life Star Trek tricorder for the first time at a U.S. scientific conference. The mobile health device, named DxtER, weighs less than five pounds and allows users to monitor five real-time health vital signs and diagnose 34 diseases without the help of a clinician.
Related Links:
Kalorama Information
Kalorama Information, (New York, NY, USA), an independent medical market research firm, estimates the market for CRISPR to be worth USD 28 billion and believes that gene editing is reaching mainstream testing. According to experts, CRISPR will be first used to treat people for blood-related diseases in a way similar to a bone marrow transplant, but to correct a person’s own blood-producing cells instead of implanting donated ones.
The 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from July 30–August 3, also featured a talk by CRISPR co-inventor Jennifer Doudna, PhD, on the future of genome engineering using this revolutionary tool, as well as a plenary on the clinical lab's critical role in combating the antibiotic resistance crisis.
Among the exhibitors at the event was Final Frontier Medical Devices, which presented its real-life Star Trek tricorder for the first time at a U.S. scientific conference. The mobile health device, named DxtER, weighs less than five pounds and allows users to monitor five real-time health vital signs and diagnose 34 diseases without the help of a clinician.
Related Links:
Kalorama Information
Latest AACC 2017 News
- Siemens Healthineers Showcases Atellica Solution at AACC 2017
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- Combating Infectious Diseases Key Focus of AACC
- World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- Opioid Drug Abuse Testing Key Topic at Congress
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
- Annual Meeting Offers Industry Education and Entertainment
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








